GDAP1 and Charcot-Marie-Tooth disease: In an original way, this study propose to assess the effect of amlexanox as readthrough molecule combined to NMD inhibitors activity, on neuronal progenitors derived from CMT patients’ hiPSCs, harboring the homozygous c.581C>G nonsense mutation in GDAP1 (p.Ser194*).